Loading, Please Wait...
BETHLEHEM, Pa., Sept. 21, 2018 (GLOBE NEWSWIRE) -- B. Braun Medical Inc., a market leader in regional anesthesia, will present its innovative line of regional anesthesia products at the American Association of Nurse Anesthetists (AANA) conference from September 21-25, 2018 in Boston, Massachusetts.
In a simulated hospital setting at booth #610, B. Braun will showcase the following products:
“We are dedicated to helping clinicians optimize the regional anesthesia process,” said Peter McGregor, Director of Marketing, Pain Control, at B. Braun Medical. “We invite attendees to explore how our products can help improve patient outcomes by visiting our hospital-like setting at AANA.”
Visitors to B. Braun’s booth at the 85th annual AANA national meeting at the Boston Hynes Convention Center also will see the B-Smart™ Injection Pressure Monitor, which provides a visual indication of high injection pressure and helps signify intraneural placement of the needle tip during peripheral nerve blocks.
*IMPORTANT SAFETY INFORMATION FOR CLOROTEKAL
®
(chloroprocaine hydrochloride)
Contraindications: Known hypersensitivity to the active substance, medicinal products of the PABA (para-aminobenzoic acid) ester group, other ester-type local anesthetics or to any of the excipients. General and specific contraindications to spinal anesthesia regardless of the local anesthetic used should be taken into account (e.g., decompensated cardiac insufficiency, hypovolemic shock, coagulopathy). Intravenous regional anesthesia (the anesthetic agent is introduced into the limb and allowed to set in while tourniquets retain the agent within the desired area). Serious problems with cardiac conduction. Local infection at the site of proposed lumbar puncture and Septicemia.
The onset of action with chloroprocaine is rapid (usually 6 to 12 minutes), and the duration of anesthesia, depending upon the amount used and the route of administration.
Warnings and Precautions:
For additional information, please see full Prescribing Information and healthcare provider information for Clorotekal® (chloroprocaine hydrochloride) at www.clorotekalusa.com.
*Clorotekal is a registered trademark of Sintetica S.A. and is manufactured for B. Braun Medical Inc.
About B. Braun
B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. Other key product areas include nutrition, pharmacy admixture and compounding, ostomy and wound care, and dialysis. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety.
B. Braun Medical is headquartered in Bethlehem, PA, and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®. Globally, the B. Braun Group of Companies employs more than 61,000 employees in 64 countries.
For more information, visit us at www.BBraunUSA.com.
Philips is the manufacturer of the Xperius ultrasound system. B. Braun Medical Inc. is the distributor of the Xperius ultrasound system.
1 Internal testing: ETRs JMLY-8ADPR2, NPAK-9VRK2K
Contact:
Constance Walker
B. Braun Medical Inc.
610.997.4216
connie.walker@bbraunusa.com